Advertisement

Tumor Biology

, Volume 35, Issue 6, pp 5281–5286 | Cite as

Serum carbohydrate antigen 242 expression exerts crucial function in the diagnosis of pancreatic cancer

  • Xueyan Li
  • Xiaozhong Guo
  • Hongyu Li
  • Hao Lin
  • Yingwei Sun
Research Article

Abstract

Pancreatic cancer has the worst prognosis of any gastrointestinal cancer, with the mortality approaching the incidence. Early detection is crucial for improving patients’ prognosis. CA242 has been widely reported to play a role in diagnosis of pancreatic cancer. However, published data on this subject are inconclusive. Therefore, we performed a meta-analysis to evaluate the diagnostic value of CA242 in pancreatic cancer. We searched all the eligible studies through PubMed, Embase, and the Cochrane Library databases without language limitation. Studies were assessed for quality using the quality assessment of studies of diagnostic accuracy (QUADAS). Positive likelihood ratio (PLR) and negative likelihood ratio (NLR) were pooled separately and compared with overall accuracy measures diagnostic odds ratio (DOR) and symmetric summary receiver operating characteristic (SROC). The PLR and NLR and their 95 % confidence interval (CI) were calculated using a fixed effects model according to the Mantel-Haensed method and random effects model based on the work of DerSimonian and Laird, respectively. A total of eight studies were included for analysis. The pooled sensitivity was 0.719 (95 % CI 0.690–0.746). The pooled specificity was 0.868 (95 % CI 0.849–0.885). The DOR estimate was performed and the result was (16.261). Our meta-analysis showed that CA242 could play an important role in the diagnosis of pancreatic cancer.

Keywords

Pancreatic cancer CA242 Diagnosis Meta-analysis 

Notes

Conflicts of interest

None

References

  1. 1.
    Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an update. Dig Dis. 2010;28:645–56.CrossRefPubMedGoogle Scholar
  2. 2.
    Bednar F, Simeone DM. Pancreatic cancer stem cell biology and its therapeutic implications. J Gastroenterol. 2011;46(12):1345–52.CrossRefPubMedGoogle Scholar
  3. 3.
    Chakraborty S, Baine MJ, Sasson AR, et al. Current status of molecular markers for early detection of sporadic pancreatic cancer. Biochim Biophys Acta. 1815;2011:44–64.Google Scholar
  4. 4.
    Tanase CP, Neagu M, Albulescu R, et al. Advances in pancreatic cancer detection. Adv Clin Chem. 2010;51:145–80.CrossRefPubMedGoogle Scholar
  5. 5.
    Lindholm L, Johansson C, Jaiisson EL, Hallberg C, Nilsson O. An immunoradiometric assay (IRMA) for the CA 50 antigen. In: Holmgren J, editor. Tumour marker antigen. Lund: Student literature; 1985. p. 123–33.Google Scholar
  6. 6.
    Gui JC, Yan WL, Liu XD. CA19–9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis. Clin Exp Med. 2013 Mar 3 [Epub ahead of print].Google Scholar
  7. 7.
    Whiting P, Rutjes AWS, Reitsma JB, Bossuyt PMM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25.PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PMM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003; 1129–35Google Scholar
  9. 9.
    Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J. 2003;327(7414):557–60.CrossRefGoogle Scholar
  10. 10.
    Walter SD. Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med. 2002;21(9):1237–56.CrossRefPubMedGoogle Scholar
  11. 11.
    Zamora J, Abraira V, Muriel A, et al. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol. 2006;6:31.PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Liao Q, Zhao YP, Yang YC, et al. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head. Hepatobiliary Pancreat Dis Int. 2007;6:641–5.PubMedGoogle Scholar
  13. 13.
    Ni XG, Bai XF, Mao YL, et al. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol. 2005;31:164–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Jiang JT, Wu CP, Deng HF, et al. Serum level of TSGF, CA242, and CA19-9 in pancreatic cancer. World J Gastroenterol. 2004;10:1675–7.PubMedGoogle Scholar
  15. 15.
    Jiang XT, Tao HQ, Zou SC. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer. Hepatobiliary Pancreat Dis Int. 2004;3:464–8.PubMedGoogle Scholar
  16. 16.
    Ozkan H, Kaya M, Cengiz A. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer. Hepatogastroenterology. 2003;50:1669–74.PubMedGoogle Scholar
  17. 17.
    Banfi G, Bravi S, Ardemagni A, et al. CA 19.9, CA 242, and CEA in the diagnosis and follow-up of pancreatic cancer. Int J Biol Markers. 1996;11:77–81.PubMedGoogle Scholar
  18. 18.
    Haglund C, Lundin J, Kuusela P, et al. CA242: a new tumor marker for pancreatic cancer: a comparison with CA19-9, CA 50, and CEA. Br J Cancer. 1994;70:487–92.PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Röthlin MA, Joller H, Largiadèr F. CA 242 is a new tumor marker for pancreatic cancer. Cancer. 1993;71:701–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Nilsson O, Johansson C, Glimelius B, Persson B, Nørgaard-Pedersen B, Andrén-Sandberg A, et al. Sensitivity and specificity of CA242 in gastrointestinal cancer. A comparison with CEA, CA50, and CA 19-9. Br J Cancer. 1992;65(2):215–21.PubMedCentralCrossRefPubMedGoogle Scholar
  21. 21.
    Jones CM, Athanasiou T. Summary receiver operating characteristic curve analysis techniques in the evaluation of diagnostic tests. Ann Thorac Surg. 2005;79:16–20.CrossRefPubMedGoogle Scholar
  22. 22.
    Walter SD. Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med. 2002;21:1237–56.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Xueyan Li
    • 1
  • Xiaozhong Guo
    • 1
  • Hongyu Li
    • 1
  • Hao Lin
    • 1
  • Yingwei Sun
    • 1
  1. 1.Department of GastroenterologyGeneral Hospital of Shenyang Military RegionShenyangChina

Personalised recommendations